Simulations Plus (SLP) Earnings Date & Reports

Key Takeaways

• Simulations Plus, Inc. (NASDAQ: SLP), a provider of modeling and simulation software for drug development, is expected to report fiscal fourth quarter 2026 results (for the quarter ended August 31, 2026) after the market closes on Thursday, October 29, 2026.
• Wall Street consensus calls for earnings per share (EPS) of $0.09 on revenue of approximately $17.44 million, according to market estimates.
• The comparison is challenging: in the same quarter a year earlier, the company posted EPS of $0.10 on revenue of $17.46 million.
• Simulations Plus has beaten consensus EPS estimates in six of its last eight quarters, most recently reporting $0.30 per share in fiscal Q3 2026 against a $0.23 estimate.
• Management's fiscal 2026 guidance calls for EPS of $0.75 to $0.85 and revenue of $79 million to $82 million.
• For more details on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, be sure to explore these dedicated pages.
• You can also discover Trending AI Robots to see how automated strategies are approaching the market.

Earnings Context and Why It Matters

Simulations Plus closes out a fiscal year that has featured strong mid-year momentum and a mixed start. The company develops software used by pharmaceutical and biotechnology companies to model and simulate drug behavior, helping clients streamline research and development and regulatory submissions. Its fiscal fourth quarter often carries seasonal weight as contracts and renewals land before the August 31 year-end. Investors will be watching whether the company can sustain the revenue strength seen in recent quarters while managing the softer growth implied by consensus estimates for the period. The results will also frame how management enters fiscal 2027, making this report a meaningful barometer for both near-term execution and longer-term demand across the life sciences software market.

Earnings Expectations

Analysts expect Simulations Plus to report EPS of $0.09 on revenue of roughly $17.44 million for the fiscal fourth quarter of 2026. That would represent a modest year-over-year decline from the prior-year quarter, when the company delivered EPS of $0.10 on revenue of $17.46 million. For context, the company reported fiscal Q3 2026 EPS of $0.30 on revenue of approximately $21.89 million, comfortably ahead of the $0.23 consensus EPS estimate. Management's full-year fiscal 2026 outlook projects EPS of $0.75 to $0.85 and revenue of $79 million to $82 million, so the fourth-quarter result will help determine whether the company lands within that guided range. Investors are likely to focus on software revenue growth, services mix, and any update to the company's forward outlook.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are monitoring a specific ticker like SLP or searching for new ideas across the market, the AI Screener offers a structured way to narrow your focus.

Market Reaction and Investor Sentiment

Sentiment heading into the report is measured, reflecting the soft year-over-year comparison embedded in consensus estimates. Simulations Plus has a track record of delivering earnings surprises, exceeding EPS expectations in six of its last eight quarters, which may temper bearish positioning. However, the fiscal fourth quarter has occasionally produced in-line or modest results given the seasonality of the business. Key risk factors include the timing of large software contracts, potential shifts in customer research and development budgets, and any foreign-exchange or acquisition-related effects. Investors will also parse management's commentary on the demand environment for biosimulation and cheminformatics software as a signal for the coming fiscal year.

Forward Outlook and Key Factors to Monitor

Following the earnings report, investors will want to watch several forward-looking signals. First, any update to guidance for fiscal 2027 will be closely read, as it sets the baseline for growth expectations over the next twelve months.

Second, the trajectory of software revenue versus services revenue matters. Software, particularly subscription-based offerings, is generally viewed as higher quality and more recurring, so the mix between these segments can influence how the market values the results.

Third, keep an eye on operating margins and expense trends. Continued investment in research and development and in the company's expanding product portfolio could pressure near-term profitability even as it supports longer-term growth.

Finally, broader industry dynamics in pharmaceutical research and development spending, as well as any commentary on client renewal activity, will help investors assess whether demand remains resilient. While these factors will not resolve in a single quarter, they collectively shape the outlook for Simulations Plus heading into fiscal 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations